Quigley earnings
This article was originally published in The Tan Sheet
Executive Summary
The Doylestown, Penn.-based firm reports a 58.1% increase in net sales for the third quarter to $15.3 mil. from $9.7 mil. in the year-ago period in an earnings announcement Oct. 27. The increase reflects a 85.1% rise in sales in the company's cold remedy segment. Sales for that division "continued to far outpace the growth in its category" for the third consecutive quarter, the firm said, noting that new product extensions of Cold-Eeze contributed to the growth. The segment's expansion also is a result of "the success of strategic advertising and marketing initiatives" and "a notable increase in consumer acceptance and expanded household penetration." Third-quarter net income was $3.0 mil. compared to $177,000 for the same period in 2004...
You may also be interested in...
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.
Philips Portfolio Includes ‘No Single Product That Does Not Use A Type Of AI,’ Says CEO And AI Thought Leader Roy Jakobs
Philips CEO Roy Jakobs talks to Medtech Insight about the medtech firm’s decade-long history of embedding AI into its products and what he expects from the newly released draft framework by the National Academy of Medicine, which he helped develop as co-chair of the Steering Committee.
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.